Fernandes Philip, O'Neil Michael, Del Valle Samantha, Cave Anita, Nagpal Dave
1 Clinical Perfusion Services, London Health Sciences Centre, London, Ontario, Canada.
2 Cardiac Care, Perioperative Cardiac Anesthesiology, London Health Sciences Centre, London, Ontario, Canada.
Perfusion. 2019 May;34(4):337-344. doi: 10.1177/0267659118813043. Epub 2018 Dec 25.
A 44-year-old male with ongoing chest pain and left ventricular ejection fraction <20% was transferred from a peripheral hospital with intra-aortic balloon pump placement following a non-ST-elevation myocardial infarction (STEMI). The patient underwent emergent multi-vessel coronary artery bypass grafting requiring veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) on post-operative day (POD)#9 secondary to cardiogenic shock with biventricular failure. Due to clot formation, an oxygenator change-out was necessary shortly after initiation. Following a positive heparin-induced thrombocytopenia (HIT) assay, a total circuit exchange was required to eliminate all heparin coating and argatroban was deemed the anticoagulant of choice due to acute kidney injury. On POD#24, the decision was made to implant a left ventricle assist device (LVAD) as a bridge to heart transplantation. There was difficulty achieving an activated clotting time (ACT) >400 s: multiple argatroban bolus doses were required, along with accelerated up-titration of infusion dosing. Despite maintaining an ACT >484 s, clot formation was observed in the cardiotomy reservoir prior to separation. Subsequently, the patient developed severe disseminated intravascular coagulopathy, with both intra-cardiac and intravascular thrombi, requiring massive transfusion and continuous cell saving due to severe hemorrhage post cardiopulmonary bypass (CPB). The patient received a total of 105 units of plasma, 74 units of packed red cells, 19 units of platelets, 13 bottles of 5% albumin, 6 units of cryoprecipitate and 2 doses of factor VIIa intraoperatively over the course of 24 hours. A total of 19.7 L of washed red blood cells were returned to the patient from the cell saver. With the LVAD in place, the patient developed transfusion-related acute lung injury and acute respiratory distress syndrome with right ventricular dysfunction requiring VA ECMO once again. On POD#30, ECMO was discontinued and the patient was discharged from the intensive care unit (ICU) on POD 66. After a very complex post-operative stay with numerous surgeries and extensive rehabilitation, the patient was discharged home with the LVAD on POD#112.
一名44岁男性,持续胸痛,左心室射血分数<20%,在非ST段抬高型心肌梗死(STEMI)后,由外周医院转入,已置入主动脉内球囊泵。患者术后第9天因心源性休克合并双心室衰竭,接受了急诊多支冠状动脉搭桥术,术中需要静脉-动脉(VA)体外膜肺氧合(ECMO)支持。由于血栓形成,开始使用ECMO后不久就需要更换氧合器。肝素诱导的血小板减少症(HIT)检测呈阳性后,需要进行全回路置换以去除所有肝素涂层,鉴于急性肾损伤,阿加曲班被视为抗凝剂的首选。术后第24天,决定植入左心室辅助装置(LVAD)作为心脏移植的过渡。很难将活化凝血时间(ACT)维持在>400秒:需要多次推注阿加曲班,并加速滴定输注剂量速率。尽管ACT维持在>484秒,但在分离前在心内直视手术储血器中观察到血栓形成。随后,患者发生严重的弥散性血管内凝血,出现心内和血管内血栓,由于体外循环(CPB)后严重出血,需要大量输血和持续细胞回收。患者在24小时的手术过程中,术中总共接受了105单位血浆、74单位红细胞悬液、19单位血小板、13瓶5%白蛋白、6单位冷沉淀和2剂凝血因子VIIa。细胞回收装置共回输19.7升洗涤红细胞给患者。LVAD置入后,患者发生输血相关急性肺损伤和急性呼吸窘迫综合征,合并右心室功能障碍,再次需要VA ECMO支持。术后第30天,停用ECMO,患者在术后第66天从重症监护病房(ICU)出院。经过非常复杂的术后住院治疗,包括多次手术和广泛的康复治疗,患者在术后第112天带着LVAD出院回家。